Search Results

ZOLL Receives Innovative Technology Contract from Vizient for TherOx SuperSaturated Oxygen (SSO 2 ) Therapy.

ZOLL ® announced today that it has received FDA clearance and CE mark* for a significant upgrade to the versatility of the Thermogard™ Temperature Management System.

ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the United States Food and Drug Administration (FDA) has approved the remedē System for conditional use with magnetic resonance imaging (MRI).

ZOLL® announced that it has entered into an agreement with BrainCool, a medical device company specializing in temperature management solutions, for the exclusive distribution of the BrainCool™ System/IQool™ System and the IQool™ System Pads in the U.S. and key markets in Europe, and are working towards expanding distribution to select markets in Asia.

ZOLL® Medical Corporation and Itamar™ Medical Ltd. announced that the two companies signed a definitive agreement under which ZOLL Medical will acquire all outstanding ordinary shares of Itamar Medical for a total value of approximately $538 million.

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”) today announced financial results and recent corporate highlights for the first quarter ended March 31, 2024.

ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the first patient has enrolled in the AMIHOT III post-approval study further evaluating TherOx® SuperSaturated Oxygen (SSO2) Therapy for the treatment of the most severe form of heart attack, left anterior descending (LAD) ST-Elevation Myocardial Infarction (STEMI).

ZOLL® Medical Corporation announced that it has successfully completed its previously announced acquisition of Itamar™ Medical Ltd., a medical device and digital health company that provides at-home testing for sleep apnea.